• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Inclusion of membrane-anchored LTB or flagellin protein in H5N1 virus-like particles enhances protective responses following intramuscular and oral im

tetano

Editor, Senior Moderator
Vaccine. 2018 Aug 29. pii: S0264-410X(18)31182-4. doi: 10.1016/j.vaccine.2018.08.053. [Epub ahead of print]
[h=1]Inclusion of membrane-anchored LTB or flagellin protein in H5N1 virus-like particles enhances protective responses following intramuscular and oral immunization of mice.[/h] Ren Z[SUP]1[/SUP], Zhao Y[SUP]2[/SUP], Liu J[SUP]3[/SUP], Ji X[SUP]2[/SUP], Meng L[SUP]2[/SUP], Wang T[SUP]2[/SUP], Sun W[SUP]2[/SUP], Zhang K[SUP]2[/SUP], Sang X[SUP]2[/SUP], Yu Z[SUP]2[/SUP], Li Y[SUP]2[/SUP], Feng N[SUP]2[/SUP], Wang H[SUP]2[/SUP], Yang S[SUP]2[/SUP], Yang Z[SUP]4[/SUP], Wang Z[SUP]4[/SUP], Gao Y[SUP]5[/SUP], Xia X[SUP]6[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] We previously demonstrated that intramuscular immunization with virus-like particles (VLPs) composed of the haemagglutinin (HA), neuraminidase (NA), and matrix (M1) proteins of A/meerkat/Shanghai/SH-1/2012 (clade 2.3.2.1) protected mice from lethal challenge with viruses from other H5 HPAI clades. The inclusion of additional proteins that can serve as immunological adjuvants in VLPs may enhance adaptive immune responses following vaccination, and oral vaccines may represent the safest choice. Here, we report the generation of H5N1 VLPs composed of the viral HA, NA, and M1 proteins and membrane-anchored forms of the Escherichia coli heat-labile enterotoxin B subunit protein (LTB) or the Toll-like receptor 5 ligand flagellin (Flic). Mice intramuscularly or orally immunized with VLPs containing LTB or Flic generated greater humoural and cellular immune responses than those administered H5N1 VLPs without LTB or Flic. Intramuscular immunization with VLPs protected mice from lethal challenge with homologous or heterologous H5N1 viruses irrespective of whether the VLPs additionally included LTB or Flic. In contrast, oral immunization of mice with LTB- or Flic-VLPs conferred substantial protection against lethal challenge with both homologous and heterologous H5N1 influenza viruses, whereas mice immunized orally with VLPs lacking LTB and Flic universally succumbed to infection. Mice immunized orally with LTB- or Flic-VLPs showed 10-fold higher virus-specific IgG titres than mice immunized with H5N1-VLPs lacking LTB or Flic. Collectively, these results indicate that the inclusion of immunostimulatory proteins, such as LTB and Flic, in VLP-based vaccines may represent a promising new approach for the control of current H5N1 HPAI outbreaks by eliciting higher humoural and cellular immune responses and conferring improved cross-clade protection.


[h=4]KEYWORDS:[/h] Chimeric VLPs; H5N1 influenza; Immunogenicity; Mucosally vaccinated; Oral immunization; Vaccine

PMID: 30172635 DOI: 10.1016/j.vaccine.2018.08.053
 
Back
Top Bottom